(Reuters) - Denmark's Novo Nordisk A/S said the U.S. Food and Drug Administration accepted a resubmitted application for its key insulin drug, Tresiba, based on interim analysis data from a clinical trial.
Tresiba, already available outside the United States, was rebuffed by the FDA two years ago on concerns that the drug could be linked to higher rates of heart attacks or strokes.
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle12
03:00 Carrier incentives stir debate over 'rewarding' offshoring12
01:02 A company Trump attacked will receive state tax breaks to keep jobs in the U.S11
23:59 Samsung Electronics says reviewing shift to holding company structure15